用小型的、自動(dòng)機(jī)技術(shù)針對(duì)靶蛋白、細(xì)胞或組織篩選大量化合物文庫(kù)以識(shí)別潛在新藥。結(jié)合基因組學(xué)和組合化學(xué)，大規(guī)模篩選為藥物和生物技術(shù)公司識(shí)別潛在新藥的能力帶來(lái)了革命。大規(guī)模篩選有賴于對(duì)要識(shí)別的靶子的數(shù)量和藥物相關(guān)分析的發(fā)展，然后可以在大量樣本中重復(fù)。一般，大規(guī)模篩選依賴于96孔板，盡管更高密度的形式也是可能的。最近，小型化和微流體方面的進(jìn)展允許在一個(gè)芯片上每天對(duì)一個(gè)靶子篩選10萬(wàn)個(gè)化合物，使得從前不可想象的大量化合物篩選成為可能。

The use of miniaturized, robotics-based technology to screen large compound libraries against an isolated target protein, cell or tissue in order to identify binders that may be potential new drugs. In conjunction with genomics (the identification of large numbers of potential therapeutic targets), and combinatorial chemistry (the production of large numbers of medicinally relevant compounds), high-throughput screening has revolutionized the capacity of pharmaceutical and biotechnology companies to identify potential new drugs. High-throughput screening depends on the development of a quantitative, pharmacologically relevant assay for the identified target, which can then be reproduced across a large number of samples. Typically, high-throughput screening has relied on 96-well plates as the standard, although higher-density formats (356, 712) are possible. Recently, advances in miniaturization and microfluidics have allowed screening of up to 100,000 compounds against a target on a single chip daily, allowing previously unimaginable amounts of compounds to be screened.